Equities Analysts Offer Predictions for BCYC FY2026 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC) – Research analysts at Leerink Partnrs issued their FY2026 earnings per share estimates for shares of Bicycle Therapeutics in a note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst J. Chang expects that the company will earn ($3.67) per share for the year. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.10. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.47 million. During the same quarter in the previous year, the firm earned ($1.16) earnings per share. The firm’s quarterly revenue was down 30.2% compared to the same quarter last year.

A number of other research analysts have also recently commented on BCYC. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday. B. Riley cut their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Stephens reaffirmed an “equal weight” rating and issued a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. HC Wainwright restated a “buy” rating and set a $33.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.14.

Bicycle Therapeutics Stock Performance

Shares of NASDAQ BCYC opened at $11.03 on Thursday. The company’s fifty day moving average price is $13.35 and its 200 day moving average price is $19.46. The company has a market capitalization of $761.62 million, a PE ratio of -3.35 and a beta of 0.93. Bicycle Therapeutics has a 1 year low of $10.91 and a 1 year high of $28.67.

Insider Activity at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 9,038 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total value of $127,345.42. Following the completion of the sale, the chief executive officer now directly owns 495,026 shares of the company’s stock, valued at $6,974,916.34. This represents a 1.79 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Santiago Arroyo sold 4,943 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total value of $69,646.87. Following the sale, the insider now directly owns 69,057 shares in the company, valued at approximately $973,013.13. This represents a 6.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,677 shares of company stock valued at $392,413 over the last quarter. 8.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Bicycle Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of BCYC. FMR LLC acquired a new stake in shares of Bicycle Therapeutics during the 3rd quarter worth approximately $3,406,000. The Manufacturers Life Insurance Company lifted its stake in shares of Bicycle Therapeutics by 33.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company’s stock valued at $2,935,000 after acquiring an additional 32,313 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in shares of Bicycle Therapeutics during the 3rd quarter valued at $10,028,000. State Street Corp boosted its holdings in shares of Bicycle Therapeutics by 233.5% during the 3rd quarter. State Street Corp now owns 86,271 shares of the company’s stock valued at $1,952,000 after acquiring an additional 60,399 shares in the last quarter. Finally, Jane Street Group LLC grew its position in Bicycle Therapeutics by 35.7% during the 3rd quarter. Jane Street Group LLC now owns 20,180 shares of the company’s stock worth $457,000 after acquiring an additional 5,310 shares during the last quarter. 86.15% of the stock is currently owned by institutional investors and hedge funds.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.